OLIN Corp (OLN) · Aug 17, 2026 · Acquisition
Merger disclosures supplemented — $6.15B 2026E Huntsman revenue vs $6.287B initially; 2027E-2030E revenue unchanged
Olin supplements its Huntsman merger proxy after shareholder suits, adding valuation detail while showing no revenue synergies and limited forecast changes.
The merger itself was already known; this filing mainly addresses execution risk. Olin and Huntsman had already filed the definitive proxy materials and scheduled both shareholder votes for August 25, 2026. The new information is that two Huntsman stockholder suits, demand letters and one Olin shareholder suit allege disclosure omissions, creating a potential delay risk even though management says the claims lack merit. 〔0〕
The forecast update is largely a clarification, not a changed operating outlook. Huntsman reduced 2026E revenue from $6.287 billion to $6.150 billion, but revenue forecasts for 2027E through 2030E were unchanged; adjusted EBITDA was reduced by only $1 million in both 2029E and 2030E.
| Key disclosure | Filing figure | Comparison |
|---|---|---|
| Huntsman 2026E revenue | $6.150B | $6.287B initial projection |
| Huntsman 2027E revenue | $6.613B | Later-year forecast unchanged |
| Huntsman 2028E revenue | $7.154B | Later-year forecast unchanged |
| Huntsman 2029E adjusted EBITDA | $914M | $915M initial projection |
| Huntsman 2030E adjusted EBITDA | $1.160B | $1.161B initial projection |
| Huntsman 2027E unlevered free cash flow | $114M | Revised methodology disclosed |
| Huntsman 2030E unlevered free cash flow | $648M | Revised methodology disclosed |
The buried strategic limitation is that the deal case includes no revenue synergies. The filing says management prepared no revenue-synergy estimates, leaving the combination's upside dependent on cost, integration or other operating benefits rather than top-line acceleration. 〔1〕
The added valuation detail improves disclosure but does not create a clear economic beat. The filing supplies debt, share-count, discount-rate, peer-multiple and standalone projection assumptions used by Lazard, Citi and Morgan Stanley, but it does not change the merger terms, raise expected synergies or remove the litigation overhang. Olin's board continues to recommend approval, so versus the standing deal expectation this is best read as a tactical proxy supplement: mostly in line on transaction economics, with modestly higher legal and execution friction. 〔2〕
Olin and Huntsman shareholder votes, August 25
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!